NMDA receptor antagonist; acts at glycine site. Neuroprotective; reduces infarct size and frequency of spreading depressions in a rat model of ischemic stroke. Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from AstraZeneca
Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies.
A glycine antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion.
Pyridazino[4,5-b]quinolinediones: a series of novel glycine site NMDA antagonists with potent in vitro and in vivo properties.
Abstracts of Papers of the ACS, 1993;205:79. Abstract.